Augustus O Okhamafe

This inventor holds 29 USPTO granted patents and 17 published patent applications, plus 5 CIPO patents and 16 EPO patents, primarily in Biopharmaceutical Formulations. Top assignees: Biomarin Pharmaceutical Inc., Novartis Ag, Xoma Technology Ltd.. Active years: 2009-2026.

USPTO Granted Patents = 29 (Patent Applications = 17)

% Patents Active = 79.3

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 5.1

ph-index = 7

Forward Citations = 159(Granted Patents)

Company Filing History:

23 out of 136

Biomarin Pharmaceutical Inc.

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

C-Type Natriuretic Peptide

TPP-1 Formulations

Skeletal Dysplasia

CLN2 Disease

Prokaryotic Phenylalanine Ammonia-Lyase

Cancer Treatment

Pharmaceutical Compositions

Raf Kinase Inhibitor

Tetrahydrobiopterin

Benzimidazolyl Pyridyl Ethers

Active Human N-Acetylgalactosamine

Antagonist Anti-CD40 Antibody

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12514906 - Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia (2026-01-06),

2. 12076372 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-09-03),

3. 11911446 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-02-27),

4. 11590204 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2023-02-28),

5. 11505790 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2022-11-22),

6. 11229687 - TPP-1 formulations and methods for treating CLN2 disease (2022-01-25),

7. RE48267 - Variants of C-type natriuretic peptide (2020-10-19),

8. 10758598 - TPP-1 formulations and methods for treating CLN2 disease (2020-09-01),

9. 10646550 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2020-05-12),

10. 10279015 - TPP-1 formulations and methods for treating CLN2 disease (2019-05-07),

11. 10221408 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2019-03-05),

12. 9907834 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2018-03-06),

13. RE46707 - Variants of C-type natriuretic peptide (2018-02-12),

14. 9567572 - Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof (2017-02-14),

15. 9216178 - Dry blend formulation of tetrahydrobiopterin (2015-12-22),

Title: Augustus O Okhamafe: Pioneering Innovations in Skeletal Dysplasia Treatment

Introduction:

Augustus O Okhamafe, a visionary inventor based in Concord, CA (US), is leaving a remarkable legacy through his innovative spirit and dedication to impacting the world positively. His unwavering commitment to pushing the boundaries of creativity and ingenuity continues to serve as an inspiration for the next generation of inventors.

Latest Patents:

Augustus O Okhamafe's latest patents include groundbreaking research on the use of variants of C-type natriuretic peptide (CNP) for treating skeletal dysplasias and associated symptoms. His novel pharmaceutical compositions and formulations offer new possibilities for addressing long bone growth, growth velocity, and other CNP-associated disorders.

Career Highlights:

With an impressive portfolio of 27 patents, Augustus O Okhamafe has established himself as a leading figure in the field of biomedical innovation. His contributions have significantly advanced the treatment options available for skeletal dysplasias, showcasing his depth of knowledge and expertise in the healthcare industry.

Collaborations:

Throughout his career, Augustus O Okhamafe has collaborated with esteemed companies such as BioMarin Pharmaceutical Inc. and Novartis AG. Working alongside talented individuals like Daniel J Wendt and Michel Claude Vellard, he has fostered a collaborative environment where ideas flourish and innovations thrive.

Conclusion:

In conclusion, Augustus O Okhamafe's pioneering work in the field of skeletal dysplasia treatment underscores his commitment to making a meaningful impact through innovation. His legacy as a visionary inventor continues to shape the landscape of biomedical research, inspiring others to push the boundaries of what is possible in the quest for improved healthcare solutions.